Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEMQ5J)

Drug Name

ME-1071 Drug Info

Synonyms

CP-3242; MBL inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha; Metallo-beta-lactamase inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 16064853
TTD Drug ID: DMEMQ5J

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazobactam	DM3XNUI	Bacterial infection	1A00-1C4Z	Approved	[3]
Ceftolozane/tazobactam	DM9QWAH	Discovery agent	N.A.	Approved	[4]
Meropenem + vaborbactam	DMOVAIX	Intra-abdominal infection	1A40	Approved	[5]
Clavulanate	DM2FGRT	Bacterial infection	1A00-1C4Z	Approved	[6]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[7]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[8]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[9]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[10]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[11]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027139)
2	Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
3	Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
4	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6	A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
7	NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
8	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
9	Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
10	Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
11	Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
12	WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.